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Huntington’s disease (HD) is an autosomal dominant neurodegenerative disease
characterized by a late clinical onset of psychiatric, cognitive, and motor symptoms.
Transcriptional dysregulation is an early and central disease mechanism which is
accompanied by epigenetic alterations in HD. Previous studies demonstrated that
targeting transcriptional changes by inhibition of histone deacetylases (HDACs),
especially the class I HDACs, provides therapeutic effects. Yet, their exact mechanisms
of action and the features of HD pathology, on which these inhibitors act remain to
be elucidated. Here, using transcriptional profiling, we found that selective inhibition of
HDAC1 and HDAC3 by RGFP109 alleviated transcriptional dysregulation of a number
of genes, including the transcription factor genes Neurod2 and Nr4a2, and gene sets
and programs, especially those that are associated to insulin-like growth factor pathway,
in the striatum of R6/1 mice. RGFP109 treatment led to a modest improvement of the
motor skill learning and coordination deficit on the RotaRod test, while it did not alter the
locomotor and anxiety-like phenotypes in R6/1 animals. We also found, by volumetric
MRI, a widespread brain atrophy in the R6/1 mice at the symptomatic disease stage,
on which RGFP109 showed no significant effects. Collectively, our combined work
suggests that specific HDAC1 and HDAC3 inhibition may offer benefits for alleviating
the motor phenotypic deficits and transcriptional dysregulation in HD.
Keywords: HDAC inhibition, RGFP109, transcriptional dysregulation, Huntington’s disease, R6/1 mouse model,
volumetric MRI
INTRODUCTION
Huntington’s disease (HD), an autosomal dominant neurodegenerative disease caused by CAG
repeat expansions in the exon I of the Huntingtin (HTT) gene (The Huntington’s Disease
Collaborative Research Group, 1993), is characterized by progressive psychiatric, motor, and
cognitive symptoms and is fatal. In HTT exon 1, normal individuals have 7–34 CAG repeats,
while HD patients display more than 40 and in juvenile cases even more than 100 CAG repeats
(Duyao et al., 1993). Currently, no disease-modifying treatment is available. Mutant HTT gene
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causes brain region-specific neuronal dysfunction and
degeneration that is most prominent in the striatum during
early disease stages and spreads to other brain regions when the
disease progresses (Tabrizi et al., 2012).
Transcriptional dysregulation is an early and central
pathogenic mechanism in Huntington’s disease which has been
demonstrated in cell and animal models of HD as well as in
human HD brain (Cha, 2000; Hodges et al., 2006; Seredenina
and Luthi-Carter, 2012). Transcriptional repression of many
genes coding for neurotransmitters, neurotrophins, and their
receptors is a hallmark of HD, while genes that are part of
stress-response pathways were shown to be upregulated in HD.
Some of the key neuronal genes that are consistently reported
to be repressed across HD patients and animal models include
brain-derived neurotrophic factor (Bdnf ), preproenkephalin
(Penk), dopamine receptor 2 (Drd2), and dopamine receptor 1a
(Drd1). Accordingly, it has been shown that overexpression of
Bdnf and Penk is neuroprotective and improves disease outcome
in HD (Zuccato et al., 2005; Zuccato et al., 2011; Bissonnette
et al., 2013). Furthermore, dopamine agonist and antagonists
play an important role in symptomatic treatment of HD patients
(Cepeda et al., 2014; Rangel-Barajas et al., 2015; Coppen and
Roos, 2017). However, the mechanisms driving transcriptional
dysregulation in HD are not fully understood. It was suggested
that mutant HTT directly interacts with transcription factors
and DNA (Benn et al., 2008). On the other hand there is strong
evidence for epigenetic mechanisms such as histone acetylation,
histone ubiquitination, histone trimethylation (H3K9me3,
H3K4me3), and DNA methylation contributing to selective
changes in gene expression in HD pathogenesis (Ferrante et al.,
2004; Ryu et al., 2006; Seo et al., 2008; Bett et al., 2009; Vashishtha
et al., 2013; Hervas-Corpion et al., 2018).
Histone hyperacetylation by histone acetyltransferases (HATs)
is generally associated with gene expression and histone
hypoacetylation by histone deacetylases (HDACs) with gene
repression (Kurdistani et al., 2004). Global as well as gene specific
histone hypoacetylation at promoters of down-regulated genes
were shown in various HD models (Sadri-Vakili et al., 2007;
Yildirim et al., 2019). Mutant HTT leads to hypoacetylation by
directly binding HATs such as CBP, reducing their activity and
resulting in gene repression (Steffan et al., 2000; NuciforaJr.,
Sasaki et al., 2001; Cong et al., 2005; Jiang et al., 2006).
Overexpressing CBP reverses these effects and leads to decreased
mutant HTT toxicity (Steffan et al., 2000; Jiang et al., 2006).
Similar neuroprotective effects are achieved by inhibiting
the opponent, HDACs. HDAC inhibition has been shown
to ameliorate transcriptional changes in HD and improve
behavioral deficits across different experimental models (Steffan
et al., 2001; Ferrante et al., 2003, 2004; Hockly et al., 2003;
Butler and Bates, 2006; Ryu et al., 2006; Kazantsev and
Thompson, 2008; Pallos et al., 2008). Beyond HD, such chromatin
targeting strategies exert therapeutic effects in other neurological
conditions such as ischemic injury, Alzheimer disease, and
Amyotrophic lateral sclerosis as previously reported by us
and others (Ryu et al., 2005; Faraco et al., 2006; Meisel
et al., 2006; Yildirim et al., 2008; Harrison and Dexter, 2013;
Schweizer et al., 2015; Yang et al., 2017). These findings
provide significant support for the disease-modifying therapeutic
potential of epigenome-targeting strategies such as inhibition of
histone deacetylation.
Initially, HDAC inhibitors have been studied and applied
in cancer research identifying non-selective HDAC inhibitors
such as Trichostatin A (TSA) and Vorinostat as anti-cancer
drugs. In recent years, however, selective HDAC inhibitors have
been developed (Wagner et al., 2015) and there is growing
evidence that especially HDAC class I inhibitors are effective in
suppressing pathogenic mechanisms in mouse models of HD
(Thomas et al., 2008; Chiu et al., 2011; Lim et al., 2011; Jia et al.,
2012, 2016; Chen et al., 2013; Suelves et al., 2017). RGFP109
is a HDAC class I inhibitor selective for HDAC1 and HDAC3.
RGFP109 confirmed safety in a recent Phase I clinical trial
in patients of Friedreich Ataxia Syndrome and enhanced the
mRNA levels of the key disease gene frataxin (FXN) in patient
blood mononuclear cells indicating its potentials for disease
amelioration (Soragni et al., 2014). In another study, RGFP109
treatment led to significantly decreased levels of L-dopa induced
dyskinesia in a Parkinson’s disease marmosets model (Johnston
et al., 2013). A short-term treatment of HD R6/2 mice with
RGFP109 modified the expression levels of 4 out of 13 measured
disease-associated genes in the striatum (Jia et al., 2012). So
far, a comprehensive investigation of the effects of RGFP109 on
different aspects of HD, such as behavioral disease phenotypes or
brain atrophy, has not been carried out.
In the present study, we tested the therapeutic effects of
the selective HDAC inhibitor RGFP109 in the R6/1 mouse
model of HD. The outcome of HDAC1 and HDAC3 inhibition
was assessed by a set of behavioral tests and genome-wide
transcriptional analysis of the striatum. Moreover, we performed
volumetric magnetic resonance imaging (MRI) of the brain
in living animals. Our results demonstrate that inhibition of
HDAC1 and HDAC3 modestly alleviates the short-term motor
skill learning deficits, accompanied by a partial repair effect on
global gene expression changes in the striatum of R6/1 mice. MR
imaging showed, on the other hand, that RGFP109 treatment
exerted only very small, non-significant changes on the atrophy
of specific brain regions in the R6/1 mice. Collectively, these
findings present evidence for beneficial effects of specific HDAC1
and HDAC3 inhibition on transcriptional dysregulation and
motor skill learning and coordination deficits, two key aspects of
HD pathology, in HD mice.
RESULTS
HDAC1 and HDAC3 Inhibition by
RGFP109 Provides a Modest Positive
Effect on Motor Learning Deficits Typical
of HD in R6/1 Mice
R6/1 transgenic mice faithfully recapitulate many of the disease
features of human HD, such as transcriptional dysregulation,
progressive impairments of both motor and cognitive functions
(Naver et al., 2003; Hodges et al., 2008; Brooks et al.,
2012; Yildirim et al., 2019), brain atrophy and mutant HTT
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accumulation (Bayram-Weston et al., 2012). In our study, to
evaluate if the specific HDAC inhibitor RGFP109 could alleviate
the transcriptional dysregulation in HD in vivo and improve
the characteristic neuroanatomical HD features and behavioral
deficits, we treated R6/1 mice (11–14 weeks of age) with
30 mg/kg (i.p.) RGFP109 five times a week for 3 weeks (total of
23 days) (Figure 1A). R6/1 mice display a range of characteristic
behavioral deficits such as motor abnormalities, learning and
memory impairments, and reduced level of anxiety (Naver et al.,
2003; Hodges et al., 2008; Brooks et al., 2012). Thus, we examined
the R6/1 mice using different behavioral tests including RotaRod,
open field, and elevated plus maze during the course of the
study (Figure 1A).
For evaluating the effect of HDAC1 and HDAC3 inhibition on
motor coordination, balance, and motor skill learning in R6/1
mice, we performed the accelerating RotaRod test. Figure 1B
(left) depicts the latency to fall as mean of four consecutive trials
for each animal. Comparison of the vehicle-treated R6/1 and
wild type animals revealed an HD-characteristic phenotype with
significantly shorter time to stay on the rod in R6/1s. The latency
to fall was significantly reduced by the main genotype effect [F(1,
40) = 23.6 with p < 0.0001] while treatment had only a minor
effect on motor coordination [F(1, 40) = 1.09 with p = 0.304].
However, mice with treatment stayed 26 s longer on the rod,
albeit not being significant (mean of all trial: 101.8 ± 44.2 s for
R6/1-vehicle and 127.8 ± 50.5 s for R6/1-RGFP109; p = 0.651)
(Figure 1B, left). This was also observed for the speed at
fall (mean of all trials: 18.1 ± 5.7 rpm for R6/1-vehicle and
21.4 ± 7.4 rpm for R6/1-RGFP109; p = 0.672) (Supplementary
Image S1A). In contrast, inhibition of HDAC1 and HDAC3 in
R6/1 mice led to a small but significant improvement in RotaRod
performance over the course of the four consecutive trials,
indicating enhanced motor learning skills in HDACi-treated R6/1
animals (q = 0.017 for trial 4 vs. trial 1 for latency to fall; q = 0.026
for trial 4 vs. trial 1 for speed at fall) (Figure 1B, middle and
right). Notably, RGFP109 treatment in R6/1 animals resulted in
a significant increase in time to stay on the rod compared to
vehicle-treated R6/1s in the fourth trial (103.1 ± 40.0 s for R6/1-
vehicle and 153.3 ± 64.6 s for R6/1-RGFP109 and a difference
of 50.2 s; q = 0.048) (Figure 1B, middle). Albeit not statistically
significant, a similar trend was observed for the speed at fall
(mean difference = 7.08; q = 0.052) (Figure 1B, right). Vehicle-
treated R6/1 mice as well as vehicle- and RGFP109-treated
wild type animals did not exhibit significant changes in motor
learning abilities during the four trials. These findings indicate
that HDAC1 and HDAC3 inhibition by RGFP109 modestly
ameliorates short-term motor learning deficits in R6/1 mice.
We next analyzed if the general locomotor activity in the
open field was also affected by RGFP109 treatment in R6/1 mice.
Locomotor activity is known to be impaired in the R6/1 line as
well as in other HD models (Naver et al., 2003; Hodges et al.,
2008). Accordingly, we observed a highly significant reduction
in the total distance traveled as well as in the average velocity
and vertical activity (supported rearing) in vehicle-treated
R6/1 animals compared to vehicle-treated wild type littermates
indicating a hypoactive phenotype in HD animals (Figure 1C and
Supplementary Image S1B). However, no significant differences
were found between vehicle- and RGFP109-treated R6/1 mice
for any of these parameters. Next, we performed the elevated
plus maze test, which has been developed for measuring anxiety
in rodents (Walf and Frye, 2007). As previously described
(Naver et al., 2003), R6/1 mice showed trends to visit the open
arms more frequently (7.6 ± 4.2 for WT-vehicle, 12.8 ± 6.0
for R6/1-vehicle; p = 0.137), spend more time (13.6 ± 11.2 s
for WT-vehicle, 26.3 ± 13.6 s for R6/1-vehicle; p = 0.163),
and travel longer distances (38.8 ± 29.2 cm for WT-vehicle,
78.0 ± 45.5 cm for R6/1-vehicle; p = 0.198) in the open arms
regardless of treatment. Taking the reduced locomotor activity
of R6/1s into account, vehicle-treated R6/1 mice displayed a
significantly less anxious phenotype than vehicle-treated wild
type mice (visits, time, and path in open arm normalized to
total path). Treatment with RGFP109 did not exert a significant
effect on this phenotype neither in R6/1 nor in wild type mice
(Figure 1D and Supplementary Image S1C).
Lastly, abnormal limb clasping upon tail suspension can be
used to demonstrate the presence of a neurological phenotype
in HD mice. At the end of our study, before the sacrifice
of mice (at 14–17 weeks of age), several R6/1 animals
exhibited first degree forelimb clasping (score 0.5). However,
RGFP109 administration did not affect the clasping behavior
(Supplementary Image S1D). During the course of the study,
body weight of the animals was not influenced by HDAC
inhibitor administration indicating that the treatment was in
general well tolerated. As expected, a reduction in the weight of
the R6/1 mice was observed with disease progression, on which
HDACi treatment showed no effect (Mangiarini et al., 1996;
Naver et al., 2003; Supplementary Image S1E).
Altogether, these results demonstrate that RGFP109 treatment
exerts a modest positive effect on the motor skill learning deficits
while not affecting the general locomotor activity or anxiety-
related phenotypes in HD mice.
RGFP109 Treatment Alleviates, in Part,
the Global Gene Expression Changes in
the Striatum of R6/1 Mice
Aberrant transcriptional regulation in brain, especially in
striatum and cortex, is an early and central feature of HD
pathogenesis in models and patients. In the R6/1 model,
consistent transcriptional dysregulation in the brain was shown
starting with the earliest microarray reports (Kuhn et al., 2007;
Benn et al., 2010) and more recently by RNA-sequencing
studies (Gallardo-Orihuela et al., 2019; Yildirim et al., 2019).
Among the genes with aberrant expression in HD striatum are
transcriptional regulators (e.g., Fos, Egr1, Npas4, and Polr2a)
as well as key neuronal genes important for neurotransmitter
signaling (e.g., Drd1, Drd2, Grin3a, and Ppp1r1b) and synaptic
plasticity (e.g., Arc and Syp) (Seredenina and Luthi-Carter, 2012;
Vashishtha et al., 2013; Yildirim et al., 2019). To examine the
impact of RGFP109 treatment on transcriptional dysregulation,
we conducted transcriptome analysis of the striatum by RNA-
sequencing (RNA-seq) (n = 5 for WT-vehicle, n = 6 for R6/1-
vehicle, n = 6 for WT-RGFP109, n = 7 for R6/1-RGFP109).
All animals were sacrificed 18 h after the final injection and
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FIGURE 1 | RGFP109 treatment improves motor learning in R6/1 mice. (A) Schematic of treatment and experimental procedure. (B) Motor performance and
learning on a RotaRod: Latency to fall as mean of all trials, latency to fall and speed at fall as learning curve over the course of four subsequent trials. (C) Open field
exploration evaluating general locomotor activity measured as total distance traveled. (D) Anxiety-related behavior determined by elevated plus maze test showing
visits to open arm and path traveled in open arm normalized to the total path. WT, wild type. Data presented as mean ± SEM; n = 10 [WT-vehicle], n = 12 (13, Open
Field) [R6/1-vehicle], n = 10 [WT-RGFP109], n = 12 [R6/1-RGF109]; *p < 0.05, **p < 0.01, ****p < 0.0001, ns, not significant by two-way ANOVA with Tukey’s
multiple comparisons test (B-left graph, C,D); #q < 0.05, ##q < 0.01, ns, not significant by mixed-effects analysis with two-stage linear step-up procedure of
Benjamini, Krieger and Yekutieli as post-tests by controlling the False Discovery Rate (individually comparing each group to each other group) (B-learning curves:
comparison of trial 4 between groups—indicated vertically, comparison of trial 4 vs. trial 1 for R6/1-RGFP109—indicated horizontally).
the striatum was used for RNA isolation and subsequent
analyses (Figure 1A).
Analysis of the RNA-seq data revealed that 1,461 genes were
significantly differentially expressed in the R6/1 striatum at the
age of sacrifice compared to wild type mice in the vehicle-
treated group (FDR, q < 0.1; log2 FC > | 0.5|) with 1,171 genes
(80%) being downregulated in R6/1 animals (Supplementary
Data Sheet S1). As expected, among these, key HD genes such
Frontiers in Molecular Neuroscience | www.frontiersin.org 4 February 2021 | Volume 14 | Article 616886
fnmol-14-616886 February 16, 2021 Time: 12:42 # 5
Hecklau et al. Histone Deacetylase Inhibition in HD
as Drd1, Drd2, Ppp1r1b, Penk, and Adora2a were downregulated.
Analysis of the RNA-seq data from the RGFP109-treated R6/1
striata showed that the HDACi treatment significantly changed
the expression of 43 genes in R6/1 animals (FDR, q < 0.1;
log2 FC > | 0.5|), of which 36 genes were also differentially
expressed in R6/1s compared to wild types (Supplementary
Data Sheet S1). Fourteen out of these 36 genes were changed
toward wild type expression levels upon RGFP109 treatment in
R6/1 animals (Figure 2A, highlighted in red). Among these are
transcription factor genes such as Neurod2, Neurod6, and Nr4a2,
the transcriptional regulator Satb2, the thyrotropin-releasing
hormone Trh, the neuropeptide-like molecule Nxph3, and the
nicotinic acetylcholine receptor Chrna4 genes. We validated the
RNA-seq findings by quantitative RT-PCR for several typical
HD genes (Drd1, Drd2, Ppp1r1b, Adora2a, Arc, Egr1, Polr2a,
and Grin3a), for the effect of HDAC1 and HDAC3 inhibition
on the transcriptional changes in R6/1s (Nr4a2, Satb2, Folr1,
and Otx2) (although not significant in qRT-PCR data), as well
as for several genes that were previously connected to motor
skill learning behavior in rodents (Dpysl2, Wars, and Cpne5)
(D’Amours et al., 2011) in the striatum of vehicle- and RGFP109-
treated wild type and R6/1 mice (Supplementary Image S2A).
The complete lists of significantly differentially expressed genes
for the R6/1 and wild type comparison as well as for the
treatment effect in R6/1 mice in RNA-seq data are presented in
Supplementary Data Sheet S1.
Further analysis of the datasets, without imposing cutoff
criteria on the data for statistical significance, revealed a
trend for a larger potential effect of RGFP109 treatment on
expression of the dysregulated genes in R6/1 striatum, as
illustrated in Figure 2A. Of the 1,171 downregulated genes in
the vehicle-treated R6/1s, expression of 21% (244) were enhanced
by >20% by the HDACi treatment of R6/1s and among these
were genes such as adrenoceptor alpha 2a (Adra2a) and 1b
(Adra1b), suppressor of cytokine signaling 3 (Socs3), and dual
specificity phosphatase 6 (Dusp6), whose expression showed a
shift toward wild type levels. Similarly, expression of 13% (39)
of the genes upregulated in the vehicle-treated R6/1 striatum
were reduced by >20% by the RGFP109 treatment and some
of these genes were 5-hydroxytryptamine (serotonin) receptor
2c (Htr2c), roundabout guidance receptor 1 (Robo1), and
dopamine receptor d3 (Drd3) (Figure 2A and Supplementary
Image S2B). To get a better functional view of genes that
were alleviated by HDACi treatment in R6/1 animals, we
performed gene ontology (GO) enrichment analysis of these
genes that were changed toward wild type expression levels in
RGFP109-treated R6/1 animals by at least 20%. These genes
were enriched for several GO terms that are relevant for
brain physiological processes, such as neuropeptide hormone
activity, regulation of secretion, and second-messenger-mediated
signaling (Supplementary Image S2C). Supplementary Data
Sheet S2 shows the complete list of enriched GO terms
(FDR, q < 0.1).
Next, in order to functionally decipher the effect of RGFP109
treatment on gene programs in the striatum of R6/1s, we
performed protein-protein interaction network analysis of the
proteins assigned from the 43 differentially expressed genes using
STRING (Szklarczyk et al., 2019) followed by gene ontology
analysis. Expanding the network analysis with 20 proteins
associated with the query proteins revealed that 15 out of
the 43 genes belong to predicted protein-protein interactions
(Figure 2B). Notably, the largest cluster in the network included
many members of the Insulin-like growth factor (IGF) pathway,
suggesting activation of this pathway by RGFP109. In line,
evaluation of the functional enrichment of all connected and
disconnected nodes in the network for GO biological process
terms revealed the enrichment of regulation of insulin-like
growth factor receptor signaling pathway as well as several other
terms that are relevant for HD pathology, such as negative
regulation of transmission of nerve impulse and learning or
memory (Supplementary Data Sheet S2).
Further, using log2 fold changes for ranking genes, we
performed gene set enrichment analysis (GSEA) to find the
gene sets associated to the functional transcriptional changes
in HD and those induced by HDAC1 and HDAC3 inhibition.
This analysis showed that normalized enrichment scores of
43% (24 out of 55) of the gene sets that were negatively
enriched in disease (R6/1-vehicle/WT-vehicle comparison) were
changed by at least 5% toward wild type levels in RGFP109-
treated R6/1 mice (enrichment scores shifting toward 0
comparing drug-treated R6/1s vs. vehicle-treated wild type mice).
Among these were gene sets associated with neuropeptide
receptor binding, negative regulation of hormone secretion,
and regulation of IFNα signaling, that were increased toward
wild type levels. In contrast, among the positively enriched
gene sets in R6/1s, only protein DNA complex and DNA
packaging complex were lowered toward wild type levels
upon treatment (by 2.4 and 2.3%, respectively). Of note, the
neuroactive ligand receptor interaction gene set showed further
enhancement of the disease-associated enrichment pattern
upon HDAC1 and HDAC3 inhibition in R6/1 animals (by
6.4%), while the remaining gene sets enriched in disease (31)
were not changed or changed by less than 5% by RGFP109
treatment and these include actin filament based movement
and potassium channel complex gene sets (Figure 2C and
Supplementary Data Sheet S2).
We next compared our results with a previous report which
examined the effects of a similar HDACi, HDACi 4b, on genome-
wide gene expression profiles in the striatum of R6/2 mice using
microarray (Thomas et al., 2008). Of 56 genes, which were shown
to be restored in the striatum by HDACi 4b treatment of R6/2
mice, 42 were detected by RNA-seq in our study. Of these 42
genes, only 6 were significantly dysregulated in the striatum
of R6/1 mice at the age of 14–17 weeks, which corresponds
to a less progressed disease stage compared to the R6/2s, and
2 of these genes, Arhgap15 and Gsto2, were restored by more
than 20% by RGFP109 treatment of the R6/1s in our study.
To explore a more inclusive list of potentially therapeutically
relevant genes, we examined all expression changes, regardless of
their statistical significance, which revealed that of the 42 genes
previously reported to be restored by HDACi 4b, 25 showed a
change toward the wild type levels after RGFP109 administration
in R6/1 mice in our study (Figure 2D and Supplementary Data
Sheet S1), providing a list of genes whose expression levels are
consistently ameliorated by specific HDAC1/3 inhibitors across
different HD models.
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FIGURE 2 | Inhibition of HDAC1 and HDAC3 by RGFP109 has a partial repair effect on global gene expression changes in the striatum of R6/1 mice. (A) 283 genes,
significantly differentially expressed between WT and R6/1 mice (black) (Cuffdiff 2; FDR, q < 0.1; log2 FC > | 0.5|), are changed toward wild type expression levels in
RGFP109-treated R6/1 animals by at least 20% using no cutoff criteria on the data for statistical significance (green). Significantly differentially expressed genes upon
RGFP109 treatment in R6/1 mice (R6/1-RGFP109/R6/1-vehicle; FDR, q < 0.1; log2 FC > | 0.5|) are framed in red. Selected genes are labeled. (B) STRING
protein-protein interaction network analysis. Forty three genes differentially expressed between R6/1-vehicle and R6/1-RGFP109 (FDR, q < 0.1; log2 FC > | 0.5|)
were used as input and assigned to proteins (query proteins). The maximum number of 2nd shell interactors was set to 20. Network nodes represent proteins.
Edges represent protein-protein associations. Disconnected nodes in the network are hidden. (C) Gene set enrichment analysis (GSEA—Broad Institute) for gene
ontology, KEGG pathway, and REACTOME pathway gene sets. Genes were ranked based on log2 fold changes. The bar graph shows gene sets with significant
different normalized enrichment scores (NES) between WT-vehicle and R6/1-vehicle mice (FDR, q < 0.1). NESs of RGFP109-treated R6/1 compared to WT-vehicle
mice are plotted for the same gene sets. Gene sets with positive NES and the top 15 gene sets with highest difference between both comparisons for negative NES
are plotted. (D) Heatmap for gene expression levels of 25 genes, that show a change toward wild type levels by RGFP109 treatment in R6/1 mice, from a list of
genes whose expression were restored by HDACi treatment in a previous study (Thomas et al., 2008). Mean FPKM value/group is shown. Each row is a gene and
each column is a group. n = 5 [WT-vehicle], n = 6 [R6/1-vehicle], n = 7 [R6/1-RGFP109].
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Collectively, RGFP109 treatment, at least to a certain extent,
repairs the transcriptional effects of mutant Huntingtin gene
expression, causing a significant change in the expression of
43 genes, in the striatum of R6/1 mice and induced collective
changes in the expression of a number of gene sets and
pathways, some of which were associated to biological functions
and processes that are relevant for neuronal physiology and
HD pathogenesis.
Effects of RGFP109 Treatment on the
HD-Associated Atrophy of Specific Brain
Areas in the R6/1 Mice Measured by
Volumetric MRI
One hallmark of HD is neuronal degeneration which manifests
predominantly in the striatum, particularly the caudoputamen
and dorsal striatum in HD patients. In addition, brain atrophy
of variable severity can be observed in several other brain
regions, such as the cerebral cortex, total white matter, amygdala,
hippocampus, and brainstem (Rosas et al., 2003; Tabrizi et al.,
2012). The R6/1 mouse model closely recapitulates the neuronal
degeneration seen in HD patient brain. These mice exhibit
progressive brain atrophy in the striatum (especially the posterior
striatum) and cortex (especially in the retrosplenial areas)
as well as a subtle expansion of posterior ventricular spaces
(Rattray et al., 2013).
By registering the Allen brain atlas to T2w MR images
(Koch et al., 2019) we used an unbiased approach to detect
regional and sub-regional changes in R6/1 mice upon RGFP109
treatment (Figure 1A). This analysis revealed 419 brain regions
and sub-regions (55% of all analyzed regions) that showed
a significant volume difference between vehicle-treated R6/1
and wild type mice at the age of 13–16 weeks of age (FDR,
q < 0.1) (Figure 3A and Supplementary Image S3A). Of
these, the majority (403 regions, 96%) exhibited a significant
volume decrease in R6/1 mice including striatum, pallidum,
hippocampal region, and piriform area. In contrast, 16 regions
(4%) showed a significant volume increase in HD mice, e.g.,
copula pyramidis, orbital area (medial part, layer 1 and 2), and
supratrigeminal nucleus (Figure 3D and Supplementary Data
Sheet S3). RGFP109 treatment did not induce any significant
changes in the volumes of the afore-mentioned 419 brain
substructures in R6/1 mice at this age. However, 61 regions
(15%) with significant decrease or increase in R6/1 animals
showed non-significant trends toward a reversal of the volume
change upon drug treatment by at least 20% (Figure 3A,
framed red). Some of these regions include central amygdalar
nucleus (medial part), pallidum (ventral region), and prelimbic
area. Supplementary Data Sheet S3 contains the complete
list of brain regions with significant volume difference in
R6/1 animals and those that show a trend toward change
by the treatment.
As the overall brain volumes in R6/1 mice were reduced
(Supplementary Image S3E, first graph), we utilized a second
approach that corrects the regional and sub-regional volumes
by the whole brain volume. This resulted in 220 regions (29%
of all analyzed regions) showing a significant change in R6/1
animals (Figure 3B and Supplementary Image S3B). 144 brain
regions with significant volume change were shared between
the two analysis strategies (Supplementary Image S3C). Similar
to the absolute volume analysis, RGFP109 treatment did not
show any significant effects on volumes of brain regions in
R6/1 mice after correcting for the whole brain atrophy. Non-
significant trends toward an improved volume change of at least
20% upon drug treatment in R6/1 mice was detectable for 25%
(55/220) of the regions showing a significant volume difference
in R6/1 mice (Figure 3B, framed red). Seventeen brain regions
and sub-regions that show a trend toward positive effect by
drug treatment by more than 20% in R6/1s were shared in
both analysis strategies. These include piriform area (molecular
layer), ectorhinal area, intermediodorsal nucleus of the thalamus,
and prelimbic area (layer 5) (Supplementary Images S3D,E
and Supplementary Data Sheet S3). Figure 3C depicts selected
regions that were previously implicated in motor skill learning
(amygdala, caudoputamen, ectorhinal cortex, entorhinal cortex,
pallidum, piriform area, primary motor cortex) in representative
examples of vehicle- or HDACi-treated wild type and R6/1 mice
(Tamakoshi et al., 2014; Scholz et al., 2015; Badea et al., 2019).
In summary, matching the Allen brain atlas to MR images
allowed us to investigate the HD mouse neuroanatomy and
the impact of RGFP109 treatment on it in great detail. While
we detected a large number of brain regions and sub-regions
with significant volume change in R6/1 animals, HDAC1 and
HDAC3 inhibition exhibited only trends toward slowing these
volumetric differences in the brains of R6/1 mice at this
progressed disease stage.
RGFP109 Treatment Does Not Affect
Aggregate Formation or Bulk Histone
H3K27acetylation Levels in R6/1 Mice
HD is characterized by mutant HTT protein aggregate formation,
which displays a histopathological basis of transcriptional
dysregulation, neuronal degeneration, and behavioral deficits.
Given the effect of RGFP109 on short-term motor skill learning,
we examined whether RGFP109 treatment has an impact on
this neuropathological hallmark of HD. For this purpose, we
analyzed EM48 immunoreactivity in striatal sections visualizing
aggregated mutant HTT. We analyzed 8 separate images per
section, each covering a 34,192 µm2 area with 123 DAPI + cells
in average in the dorsal stratum directly lateral to the lateral
ventricle. By using ImageJ software, we defined particles larger
than 15 µm2 as nuclei. Blinded manual counting of the
number of aggregates showed that RGFP109 did not affect
the number of mutant HTT protein aggregates in R6/1 mice
(Supplementary Image S4A).
To examine the effects of RGFP109 treatment on global
histone acetylation, we determined bulk acetylation patterns
at lysine 27 of histone H3 (H3K27ac) in protein extracts of
striatal tissue via immunoblotting. Increased H3K27ac levels
can be found at active promoters and enhancers indicating
high transcriptional activity (Wang et al., 2008). Our Western
blotting analysis showed no differences in acetylated H3K27
levels between R6/1 and wild type mice, regardless of treatment.
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FIGURE 3 | Effect of RGFP109 treatment on HD-associated atrophic brain substructures in R6/1 mice. Mouse brain MR images were registered to the Allen brain
atlas. Volumes of substructures (absolute or normalized to whole brain volumes) were analyzed by two-sample t-test (FDR, q < 0.1). (A) Mean absolute volume
differences of brain regions with significant volume change in R6/1 compared to WT mice (419). (B) Mean relative volume differences of brain regions with significant
volume change in R6/1 compared to WT mice (220). (A,B) Black: substructures affected positively by drug (not significant; red frame: >20% of R6/1-WT volume
difference); Gray: substructures affected negatively by drug (not significant). (C) MR images, exemplarity shown for three individuals; selected regions are
color-coded. Anatomical labels are based on the Allen brain atlas. (D) Absolute volumes of selected brain regions. Data presented as mean ± SEM; n = 10
[WT-vehicle], n = 13 [R6/1-vehicle], n = 10 [WT-RGFP109], n = 12 [R6/1-RGFP109]; *q < 0.05, **q < 0.01, ***q < 0.001, ****q < 0.0001, ns, not significant.
As control for equal histone amounts, we determined total H3
levels from the same samples. Similarly, we did not observe
differences between the groups (Supplementary Image S4B).
While we did not detect increases in global H3K27ac patterns
in striatum by the HDACi treatment, temporally dynamic
and site-specific changes in acetylation levels not detected
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by immunoblotting of total tissue could be associated to the
transcriptional changes observed in HD.
DISCUSSION
This study suggests that treating HD mice with a specific
HDAC1 and HDAC3 inhibitor has benefits on multiple aspects
of HD. Inhibiting histone modifying enzymes, in particular
class I HDACs, has been previously shown to improve disease
features, such as the phenotypic and neuropathological deficits
and dysregulation of selected genes, in various models of HD
(Thomas et al., 2008; Chiu et al., 2011; Lim et al., 2011; Jia
et al., 2012, 2016; Chen et al., 2013; Suelves et al., 2017). The
goal of our study was to evaluate the effects of the specific
HDAC1 and 3 inhibitor RGFP109 in an unbiased approach
on the genome-wide transcriptional dysregulation and on the
phenotypic deficits in HD mice using the R6/1 model. Further,
by performing MRI measurements on living mice, we conducted
a detailed analysis of the brain volumetric changes in the R6/1
mice. Our findings demonstrate that the specific inhibition of
HDAC1 and HDAC3 by RGFP109 modestly improves the motor
learning skills and alleviates, at least to a certain extent, the
dysregulation of a number of genes and gene sets in the R6/1
mice. By volumetric MRI, we detected extensive atrophic changes
in the brains of the R6/1 mice, on which RGFP109 exerted
no significant effects. Given our results and data from others,
early targeting of transcriptional dysregulation by specific HDAC
inhibition may alleviate key transcriptional and phenotypic
aspects of HD pathology.
In a previous study, a short-term treatment regime with
RGFP109 (subcutaneous injections of 150 mg/kg/day for 3 days)
partially reversed four selected disease-associated genes in the
striatum in HD R6/2 mice as measured by PCR (Jia et al., 2012).
However, the effects of RGFP109 treatment on the behavioral
deficits and on gene expression throughout the genome as well as
on the brain atrophy have not been evaluated in HD. Here, using
the R6/1 mice, which is less progressive than the R6/2 model,
we chose to use a lower therapeutic dose of 30 mg/kg based on
a previous Parkinson’s disease study (Johnston et al., 2013) and
applied a longer treatment regime (3 weeks with five injections
per week), aiming to minimize potential toxic side effects by
reducing high drug exposure.
Among the most characteristic behavioral deficits in HD mice
are motor impairment and deficit in motor skill learning, which
are caused by the dysfunction of corticostriatal circuits (Backman
et al., 1997; Lawrence et al., 2000; Cybulska-Klosowicz et al.,
2004; Mazarakis et al., 2005). The RotaRod task is a useful
marker for detecting early HD phenotypes in R6/1 animals
from as early as 8 weeks of age (Brooks et al., 2012). Our
study demonstrates that 3-week-long treatment with 30 mg/kg
RGFP109 modestly ameliorates motor skill learning deficits in
this mouse model of HD. While we obtained this finding by
testing the animals on the RotaRod for up to four trials on the
same day, in future studies, it would be important to analyze
the animals across several days to assess learning over longer
time frames as well as to use modified RotaRod protocols or
other behavioral tests to better distinguish motor skill learning
from motor coordination and balance. In line with our findings,
Suelves et al. demonstrated that selective HDAC3 inhibition
by RGFP966 in the HdhQ7/Q111 knock-in mouse model of
HD (50 mg/kg of RGFP966 three times per week from 3 to
6.5 months) prevents corticostriatal-dependent motor learning
deficits from trial four on testing animals for four times per day
for 3 consecutive days (Suelves et al., 2017). Similarly, treatment
of N171-82Q HD mice with RGFP966 over a period of 10 weeks
with 10 or 25 mg/kg per week showed improved motor function,
accompanied by neuroprotective effects on striatal volume, and
significant alterations of the expression of 3 immune pathway
genes (chemokine (C-C motif) ligand 17 (Ccl17), macrophage
migration inhibitory factor (Mif ), interleukin 13 (Il13); measured
by PCR) (Jia et al., 2016). Notably, in the latter study, the
beneficial effects of RGFP966 on the RotaRod task was observed
in female HD mice only, suggesting potential differences in
HDACi’s effects depending on sex. While a sex comparison was
not within the scope of our study, it would be important to test
RGFP109, which showed positive effects in male R6/1 mice in
this current study, also on female R6/1s in future. In a mouse
model of Friedreich ataxia prolonged RGFP109 treatment led to
modest improvements in motor coordination performance and
locomotor activity (Sandi et al., 2011). It has been shown that
improvement on the RotaRod mainly requires a change in the
motor strategy to master the task rather than an enhancement in
general locomotor activity (Buitrago et al., 2004). Accordingly, we
did not observe improvement in general locomotor activity in the
open field test upon RGFP109 treatment in R6/1 animals.
To investigate the potential molecular correlates of our
behavioral findings, we carried out a genome-wide analysis of
the transcriptional changes, which was not done before in the
afore-mentioned studies, in the striata of vehicle- and drug-
treated R6/1 and wild type mice. Our RNA-seq data showed the
altered expression of a large number of genes in the striatum
of R6/1 mouse, which included also those that are well-known
to be dysregulated in HD, e.g., Drd1, Drd2, Penk, and Adora2a
(Seredenina and Luthi-Carter, 2012). RGFP109 administration
showed, in part, repair effects on the global aberrant gene
expression changes in the striatum of R6/1 mice, affecting 43
individual genes significantly. Some of these genes were the
thyrotropin-releasing hormone gene Trh, the neuropeptide-like
molecule gene Nxph3, the nicotinic acetylcholine receptor gene
Chrna4, and transcriptional regulator genes such as Neurod2,
Neurod6, Nr4a2, and Satb2, whose change in expression may
likely result in alterations in the expression of their target genes.
Further, Arhgap15 (Rho GTPase activating protein 15) and Gsto2
(Glutathione S-Transferase Omega 2), genes whose expression
were completely rescued in a previous report by the HDAC1 and
HDAC3 selective inhibitor HDACi 4b in R6/2s (Thomas et al.,
2008), were also restored in our study upon RGFP109 treatment
in R6/1s, supporting a similar mode of action of these selective
HDAC inhibitors across different models of HD. Of note, loss
of Arhgap15 gene, a member of the Rac signaling pathway, was
shown to cause decreased synaptic density and cognitive deficits
in mouse and its mutations were identified in association with
neurological and cognitive deficits in patients with Intellectual
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Disability (Zamboni et al., 2018), revealing the rescue of its
expression by HDACi treatment as potentially therapeutically
relevant in HD. Beyond these single gene expression changes,
we found that a number of gene sets and pathways associated
with neurophysiological functions relevant for HD pathology
were changed upon treatment and these changes could be linked
to the observed phenotypic changes. Notably, all three analyses
tools we utilized, Gene ontology, GSEA and String network,
commonly revealed enrichment of hormone activity related
pathways, indicating in particular the activation of Insulin-like
growth factor pathway by RGFP109 treatment. Both IGF-1 and
IGF-2 were previously reported to exert robust protective effects
in HD (Lopes et al., 2014; Garcia-Huerta et al., 2020), suggesting
that induction of IGF pathway by RGFP109 may be one of
the key mechanisms contributing to RGFP109’s beneficial effects
observed in our study.
In an animal study of Friedreich Ataxia it was shown that
long-term RGFP109 treatment (100 mg/kg over a period of
5 months with five injections per week) increased especially
local H3K9ac and H4K5ac levels directly at the frataxin gene
accompanied by higher frataxin gene expression levels in mouse
brain, whereas global H3 and H4 acetylation patterns did not
significantly increase by the drug (Sandi et al., 2011). Next
to the spatial changes of specific histone acetylation patterns,
temporal differences of global and local histone acetylation
have been observed in another Friedreich Ataxia mouse study
using a single RGFP109 administration (with 150 mg/kg) (Rai
et al., 2010). In this study, global H3 acetylation in the brain
increased to a maximum level at 4 h after injection and totally
disappeared at 24 h, whereas H4K5ac and H3K14ac at the
frataxin gene were shown to increase between 12 and 24 h (Rai
et al., 2010). In contrast to the aforementioned studies in mouse
models of Friedreich Ataxia, we did not observe increased global
H3K27 acetylation by RGFP109 treatment measured by Western
blotting of total striatal extracts. Supporting our findings of no
change in global histone acetylation after RGFP109 treatment,
a previous report showed histone acetylation changes only at
specific promoters using a similar HDAC inhibitor, HDACi 4b,
in the R6/2 mice (Thomas et al., 2008).
Aiming at examining different key features of HD, on which
RGFP109 treatment may have an effect, we performed MRI
measurements to study the structural brain changes in HD mice.
By registering the Allen brain atlas to MR images, we provided
a complete list of regional and sub-regional volumetric changes
of the brains of R6/1 animals, which by far expands the set of
regions so far shown to be changed in this HD model. Using
longitudinal in vivo MRI, a previous study detected reduction in
both global brain volume as well as brain sub-regional volumes
when corrected for global volume change in R6/1 mice over
time, showing ubiquitous shrinkage of the striatum and the
somatosensory cortices (Rattray et al., 2013), comparable with
what we detected with our approach here. In contrast, increases
in regional and sub-regional volumes when corrected for whole
brain volume should be viewed cautiously, as they indicate a less
pronounced shrinkage of that brain area compared to the volume
reduction of the whole brain, rather than an actual regional
size increase. In pre-symptomatic and symptomatic HD patients
progressive whole brain volume loss is evident (Tabrizi et al.,
2012). Furthermore, in addition to the striatum, other brain
regions known to be affected in HD patients, such as cerebral
cortex, amygdala, hippocampus, and brainstem (Rosas et al.,
2003), are also changed in R6/1 mice. Similar to the modest
transcriptomic changes we observed upon RGFP109 treatment,
volumes of specific brain regions and sub-regions showed only
non-significant trends toward an alleviation upon HDAC1 and
HDAC3 inhibition in R6/1 mice at this disease stage. Of note,
these regions include some of the brain areas that were previously
implicated in motor skill learning behavior in rodents, such
as the amygdala, ectorhinal cortex, entorhinal cortex, pallidum,
piriform area, and primary motor cortex (Tamakoshi et al., 2014;
Scholz et al., 2015; Badea et al., 2019).
In summary, our study suggests that treatment with the
HDAC inhibitor RGFP109 provides benefits on transcriptional
dysregulation and motor skill learning and coordination deficits,
while not affecting the locomotor and anxiety-like deficits and
the progressive brain atrophy in the R6/1 mice. Further studies
should include also relevant immunohistochemical assessments
of the brain for elucidating potential synaptic plasticity changes
that may contribute to the observed phenotypic effects of HDAC
inhibition in HD mice. Although the R6/1 line recapitulates
several key features of HD, such as motor and cognitive
deficits, transcriptional dysregulation, accumulation of mutant
Htt aggregates and brain atrophy, establishing direct mechanistic
links between molecular pathology and specific behavioral
deficits has been a challenge so far (Rattray et al., 2013). Further
work using an HD mouse model with slower progression,
intervention earlier in the time course of pathology, a longer
treatment regime with various doses or a combination of these
factors in a well-powered sex-balanced cohort may enhance
the leveraging of the therapeutic potentials of this selective
HDAC inhibitor in HD. Nevertheless, we have demonstrated
that HDAC1/3 inhibitor RGFP109 modestly improved motor
skill learning deficits and alleviated transcriptional dysregulation,
characteristic disease features, in HD mice. Epigenome-targeting
strategies may be viable approaches for targeting transcriptional
dysregulation in HD and also in other neuropsychiatric diseases
without significant genetic causation.
MATERIALS AND METHODS
Animals
Hemizygous R6/1 mice, expressing exon 1 of the human HTT
gene with an estimated repeat expansion range of 115–150
CAGs, were purchased from the Jackson Laboratory. R6/1
mice were maintained on a C57BL/6J background crossing
male R6/1 with female C57BL/6J. Genotypes were determined
by PCR analyses (R6/1-fwd: 5′-CCGCTCAGGTTCTGCTTTTA-
3′; R6/1-rev: 5′-GGCTGAGGAAGCTGAGGAG-3′). The repeat
length was 143 ± 4 CAGs, as detected by sequencing of the
genotyping PCR products of selected animals (including some of
the mice used in this study). Littermates were randomly divided
into four groups: WT-vehicle (n = 10), R6/1-vehicle (n = 13),
WT-RGFP109 (n = 10), R6/1-RGFP109 (n = 12). All mice used
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in the present study were housed together in groups of maximal
four animals; if possible, genotype and treatment were mixed in
individual cages. Weight of the mice were monitored throughout
the study. No animal was excluded due to excess weight loss
(exclusion criterium: ≥25% weight loss compared to the weight
at the start of the experiment). One animal (R6/1-vehicle) died
during the course of the experiment (after completion of the MRI
measurement and open field test, before performing Rotarod and
elevated plus maze tests) due to unknown reasons. Animals were
housed under pathogen free conditions with ad libitum access
to food and water on a 12 h light/12 h dark cycle at constant
temperature (22 ± 2◦C) and humidity (55 ± 10%). All animal
experiments were approved by the local animal care committee
of Charité-Universitätsmedizin Berlin and by the Landesamt für
Gesundheit und Soziales Berlin (license number G0314/16) and
conducted according to the institutional guidelines. All efforts
were made to minimize all unnecessary suffering of animals.
In line with our license for animal experiments and the 3Rs
principles, for reducing the data variation and thereby keeping
the required number of mice for the experiments to a minimum,
only male mice were used in this study.
RGFP109 Treatment of Mice
The HDAC1 and HDAC3 inhibitor RGFP109 (RG2833; CAS
No. 1215493-56-3) was purchased from Selleckchem. RGFP109
was dissolved in dimethyl sulfoxide and diluted in 0.9% NaCl
(1:2) directly before use (final concentration: 15 mg/ml). Mice
were administered RGFP109 (30 mg/kg body weight) or an
equal volume of vehicle solution by intraperitoneal injections
five times a week for 3 weeks (total of 23 days) starting at the
age of 11–14 weeks. All injections and behavioral tests were
done around the same time of the day to avoid any biochemical
and physiological changes over the experiments. Mice were
deeply anesthetized using isoflurane and sacrificed by cervical
dislocation 18 h after the final injection. Brains were removed
and separated into right and left hemispheres. One hemisphere
was flash frozen at −80◦C in methyl butane (Sigma-Aldrich)
for immunohistochemical analysis, one was further dissected for
RNA extraction and immunoblot analyses of striatum.
Behavioral Assessment
Motor coordination, balance as well as motor skill learning
were assessed by accelerating RotaRod performance test. The
open field test was used to examine general locomotor activity.
Mouse emotional state, fearfulness, arousal, and anxiety were
evaluated by the elevated plus maze test assessing exploration
and motor activity in a new open environment. On the day of
the individual tests, animals were moved to the test room 30 min
prior to the start of the test to allow sufficient time to habituate.
All data recorded, regardless of individual behavior, were used
for the analyses.
At the end of the treatment course, mice were tested for
forelimb and hindlimb clasping behavior by suspending each
mouse by the tail, 20 cm above their home cage for up to
30 s (lack of any clasping behavior scored 0; rapid movement
of forelimbs scored 0.5; forelimb clasping behavior toward the
abdomen scored 1; forelimb and hindlimb clasping behavior
toward the abdomen scored 2).
Accelerating RotaRod
One day before the actual test, mice were trained on the RotaRod
(TSE Systems) three times at constant speed (4 rpm for 60 s)
and two times with accelerating speed (4–40 rpm over a period
of 5 min) with 30 min interval between the sessions. During the
training mice were placed back on the rod if they have fallen
down. On the following day data were recorded for four test trials
using the TSE RotaRod software, which detects the latency to fall
in seconds and the rod rotational speed at fall in rpm. The test
trials were done by accelerating the rod from 4 to 40 rpm over a
period of 5 min with at least 30 min interval between the sessions.
The rod was cleaned between animal trials to remove any odors.
Open Field
The open field test was performed in a gray open-top 50× 50 cm
arena (height 40 cm) located in a sound-attenuated observation
chamber. Mice were individually placed near the wall of the
box and locomotor activity was measured as total distance
traveled and average velocity over a period of 10 min. VideoMot2
Software, TSE Systems was used to track and record all animals
(standard measuring mode based on center of gravity). Vertical
activity (supported rearing) was manually assessed analyzing the
recorded videos (experimenter was blinded for treatment and
genotype). The field was thoroughly cleaned between the animals
to avoid any odor.
Elevated Plus Maze
The elevated plus maze test was performed in a sound-attenuated
observation chamber. The maze configuration consisted of five
main regions: two open arms (29.5 × 5 cm), two closed arms
(29.5 × 5 cm) and a middle area connecting the arms. The
plus maze was raised 68 cm above the floor. Animals were
placed in the center of the maze toward one of the closed arms.
Movements were tracked (standard measuring mode based on
center of gravity) and recorded for 5 min using VideoMot2
Software (TSE Systems). Number, duration, and path of visits
to the open arms were calculated. The maze was rigorously
cleaned between the animals to remove any scent clues left by the
previous subject mouse.
MRI Measurements
MRI measurements were performed under 1–2% isoflurane
anesthesia in a 70:30 nitrous oxide:oxygen mixture. Temperature
was maintained through a circulating warm water system.
Respiration rate was monitored during the measurements (Small
Animal Instruments, Inc., Stony Brook, NY). T2-weighted
images were acquired on a 7T MR scanner (PharmaScan
70/16 US; Bruker, Ettlingen, Germany) using a 20 mm
quadrature volume resonator (Rapid Biomed). To cover the
whole brain, a 2D T2-weighted RARE pulse sequence was
used with 32 contiguous axial slices with 0.5 mm slice
thickness and in-plane field of view of 25.6 × 25.6 mm. The
imaging parameters were: matrix size 256 × 256, echo time
spacing 1TE = 12 ms, repetition time TR/effective echo time
TE = 4,200/36 ms, bandwidth = 46,875 Hz, RARE factor 8, 4
averages, acquisition time 6:43 min.
The Allen brain atlas (Lein et al., 2007) was registered to
individual MR images using the MATLAB toolbox ANTX (Koch
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et al., 2019) and the volume of each brain region was measured in
mm3. For statistical comparison of brain region volume between
groups a t-test (FDR, q < 0.1) was applied. Only regions with a
size of >0.1mm3 (corresponding to 20 voxels) in at least one of
the analyzed groups were included in the analysis. Both, absolute
brain region volumes as well as brain region volumes normalized
to whole brain volume were evaluated.
Gene Expression Analysis by RNA-Seq,
RNA-Seq Data Analysis, and qRT-PCR
RNA Isolation
Flash-frozen tissues were homogenized in QIAzol Lysis Reagent
(Qiagen) followed by RNA extraction using the miRNeasy Kit
(Qiagen). Libraries for RNA-seq analysis were prepared using the
TruSeq RNA kit from Illumina. Two pools with twelve libraries
each [pool 1: WT-vehicle (n = 3), R6/1-vehicle (n = 3), WT-
RGFP109 (n = 3), R6/1-RGF109 (n = 3); pool 2: WT-vehicle
(n = 2), R6/1-vehicle (n = 3), WT-RGFP109 (n = 3), R6/1-
RGF109 (n = 4)] were sequenced on a Illumina HiSeq4000
instrument (1× 51 bp).
RNA-Seq Mapping and Analysis
Raw single-end reads of cDNA fragments were aligned to
the mouse transcriptome (RefSeq, mm10) using the “RNA-
Seq Alignment Workflow” from BaseSpace, Illumina (version
1.1.0) with STAR aligner (version STAR_2.5.0b) for mapping
and Cufflinks (version 2.2.1) for fragments per kilobase of exon
per million fragments mapped (FPKM) estimation of reference
genes. Differential gene expression analysis was performed
using “Cufflinks Assembly & DE Workflow” from BaseSpace,
Illumina (version 2.1.0) with Cuffdiff 2 (Cufflinks, version
2.2.1). Differential expressed genes with FDR, q < 0.1 were
considered significant.
STRING Analysis
Protein-protein interaction network analysis was performed
using STRING v11 (Szklarczyk et al., 2019). 43 genes differentially
expressed between R6/1-vehicle and R6/1-RGFP109 (FDR,
q < 0.1; log2 FC > | 0.5|) were used as input and automatically
assigned to proteins by the program (Gm11549 could not
be assigned). The minimum required interaction score was
set to 0.7 (high confidence). The maximum number of 2nd
shell interactors was set to 20. The full network is shown,
meaning the edges indicate both functional and physical
protein associations. All interaction sources were used (text-
mining, experiments, databases, co-expression, neighborhood,
gene fusion, co-occurrence). Functional enrichment of the
network for gene sub-ontology “biological process” was evaluated
from all 1st shell (query proteins) and 2nd shell (max 20) proteins.
GOrilla Analysis
Functional enrichment for gene ontology terms (biological
process, molecular function, and cellular component) were
calculated using the two unranked list approach (target and
background lists) from GOrilla (Eden et al., 2009). As target gene
list all genes significantly different in R6/1-vehicle/WT-vehicle
comparison (FDR, q < 0.1; log2FC > | 0.5|) and affected by
RGFP109-treatment in R6/1 mice by at least 20% (283) were used.
All expressed genes, with FPKM > 0.1 in at least one sample
(18,844) were used as background.
Gene Set Enrichment Analysis
For gene enrichment analysis only genes with FPKM >0.1 in
at least one of the groups analyzed were used. Pseudocounts
of 0.05 FPKM were added to every gene to circumvent inflated
fold changes at low expressed genes. Mouse gene symbols
were converted into human gene symbols using gene IDs
from BioMart - Ensembl. Enriched genes sets were analyzed
using the software from Broad Institute [GSEA (Mootha
et al., 2003; Subramanian et al., 2005) with MgSigDB gene
set collections for gene ontology, KEGG, and REACTOME
pathways]. One thousand gene-set-wise permutations were
performed to generate the null distributions. Genes were ranked
in descending order based on log2 fold changes. Enrichment
scores were calculated using the classic statistic (unweighted).
Gene sets with FDR, q < 0.1 were considered significant.
Quantitative PCR
cDNA synthesis was performed with M-MLV reverse
transcriptase (Promega) and random hexanucleotides. mRNA
expression levels were assessed by quantitative real-time PCR
using SYBR Green dye-based PCR amplification (Thermo Fisher
Scientific) and the QuantStudio 3 detection system (Applied
biosystems). Primer sequences are listed in Supplementary
Table S1. mRNA expression levels were calculated relative
to housekeeping gene Actb according to following equation:
2[Ct(Actb)−Ct(targetgene)].
Immunoblot Analysis
Flash-frozen tissues were homogenized in RIPA buffer [50 mM
Tris pH7.4, 150 mM NaCl, 1% Triton X-100, 0.1% SDS, 1%
sodium deoxycholate and protease inhibitor cocktail (Thermo
Scientific)], incubated for 2 h at 4◦C, sonicated and clarified
(12,000 × g). Equal amounts of protein (20 µg) were
subjected to SDS-PAGE and subsequently transferred to a
nitrocellulose membrane. Membranes were blocked and then
incubated with primary antibodies (anti-H3K27ac, abcam; anti-
H3, Cell Signaling Technology; anti-β Actin, Cell Signaling
Technology) at 4◦C overnight. Staining with secondary HRP-
conjugated antibody was performed at room temperature for 1 h.
Detection of the membrane was carried out using SuperSignalTM
West Dura Extended Duration Substrate (Thermo Fisher
Scientific). Histone intensities were compared and normalized
to beta-Actin intensities from the same blot using ImageJ
(ImageJ software, NIH).
Immunohistochemistry
The hemispheres were cut in coronal sections of 30 µm using
a Leica CM1950 cryostat. Sections were dried on glass slides at
room temperature before fixating in an Aceton:Methanol (1:1)
solution for 10 min at −20◦C. After a short drying period,
sections were rehydrated in PBS and blocked for 1 h in 10% goat-
serum in PBS with 0.1% Triton-X 100. Huntingtin aggregates
were stained at 4◦C over night (EM48, Millipore; 1:500, diluted
in 10% goat-serum in PBS). Slides were washed in PBS and
incubated with a secondary antibody (anti-mouse, Rhodamine
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Red-X- conjugated, Jackson ImmunoResearch; 1:1,000, diluted
in 10% goat-serum in PBS). After washing sections were stained
with DAPI, washed, and mounted in Immumount.
Image acquisition was performed using a Nikon Spinning Disk
Confocal CSU-X microscope equipped with a Nikon Plan Fluor
40x/1.3 DIC H N2 objective and Andor iXon3 EMCCD DU-888
Ultra camera. Images were acquired using Nikon NIS-Elements
(version 5.10) imaging software.
For HTT-aggregate quantification, 8 spatial separated z-stack
images (21 images with 500 nm z-steps) of one striatal section
per animal were acquired and analyzed. HTT aggregates were
counted manually based on maximum intensity projections of
each stack (ImageJ software, NIH). Experimenter was blinded for
treatment and genotype. Individual nuclei within tissue sections
were identified using the DAPI signal. Using ImageJ, sum slice
projections were created for each z-stack image followed by
background signal subtraction (rolling ball radius: 15 pixels).
A binary image was created, and the watershed method was used
to separate touching objects. Particles larger than 15 µm2 were
defined as nuclei.
Statistical Analysis
Behavioral, qPCR, immunohistochemistry, and immunoblot data
were analyzed using the Graphpad Prism 6.0 and 8.0 software.
The statistical tests included unpaired, two-tailed Student’s
t-test (used for analysis of clasping behavior and Huntingtin
aggregate data), two-way ANOVA followed by Tukey’s multiple
comparisons test (for measuring the response to genotype and
treatment; used for RotaRod, Open field, elevated plus maze and
Western blotting data), and mixed-effects analysis with two-stage
linear step-up procedure of Benjamini, Krieger and Yekutieli
as post-tests (for repeated measures data; used for RotaRod
learning curve data) as indicated in each figure legend. Statistical
comparisons, values for n and p (unpaired, two-tailed Student’s
t-test and two-way ANOVA) or q (mixed-effects analysis) are
indicated in the figure legends. Differences with p < 0.05 or
q < 0.05 were considered significant. Visualizations of RNA-
seq and MRI data and their statistical results were done in R
or with Graphpad Prism 6 software. We use the term “trend”
for referring to non-significant changes that are below the
significance threshold in the respective experiments.
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